BACKGROUND: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear. METHODS: We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3-5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy. RESULTS: Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients. CONCLUSIONS: Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.
BACKGROUND: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear. METHODS: We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3-5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy. RESULTS: Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients. CONCLUSIONS: Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.
Authors: Marinus H J van Oers; Martine Van Glabbeke; Livia Giurgea; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Mars van t Veer; Andrej Vranovsky; Harald Holte; Anton Hagenbeek Journal: J Clin Oncol Date: 2010-05-03 Impact factor: 44.544
Authors: Edward J Stepanski; Mark S Walker; Lee S Schwartzberg; L Johnetta Blakely; Jason C Ong; Arthur C Houts Journal: J Clin Sleep Med Date: 2009-04-15 Impact factor: 4.062
Authors: R Pettengell; C Donatti; P Hoskin; C Poynton; P J Kettle; B Hancock; S Johnson; M J S Dyer; S Rule; M Walker; D Wild Journal: Ann Oncol Date: 2007-12-03 Impact factor: 32.976
Authors: Lisa M Hess; Zhanglin Lin Cui; Yixun Wu; Xiaohong Li; Astra M Liepa; Sarah M Abraham; William Schelman Journal: J Gastrointest Cancer Date: 2018-03
Authors: David Aguiar-Bujanda; María Jesús Blanco-Sánchez; María Hernández-Sosa; Saray Galván-Ruíz; Samuel Hernández-Sarmiento Journal: Cancer Manag Res Date: 2015-10-27 Impact factor: 3.989